<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737071</url>
  </required_header>
  <id_info>
    <org_study_id>HUS21372018</org_study_id>
    <nct_id>NCT03737071</nct_id>
  </id_info>
  <brief_title>The Effects of Low Carbohydrate Diet on Liver Fat Content and Mitochondrial Fluxes</brief_title>
  <official_title>The Effects of Low Carbohydrate Diet on Liver Fat Content and Mitochondrial Fluxes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether a low carbohydrate diet decreases hepatic
      lipid content and changes hepatic mitochondrial flux in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators will examine whether a low carbohydrate diet will change
      hepatic lipid content and mitochondrial flux in humans. Before and after a low carbohydrate
      diet intervention, rates of hepatic mitochondrial flux will be assessed using positional
      isotopomer analysis of 3-13C-lactate during a 3 hour basal period. Rates of whole body
      ketogenesis will be determined using [13C4]β-hydroxybutyrate, and whole body glucose
      metabolism will be measured using [2H7]glucose. Body composition will be determined with
      bioelectrical impedance; hepatic lipid content will be measured with MRS. Whole-body
      oxidation of lipids, carbohydrates and protein will be determined using indirect calorimetry.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic triglyceride content</measure>
    <time_frame>1 week</time_frame>
    <description>Change in hepatic triglyceride content will be measured using 1H magnetic resonance spectroscopy (MRS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hepatic mitochondrial flux</measure>
    <time_frame>1 week</time_frame>
    <description>Change in the rate of hepatic mitochondrial flux (Vcs) will be assessed using 3-13C-lactate infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in beta-hydroxybutyrate production rate</measure>
    <time_frame>1 week</time_frame>
    <description>Change in the rate of beta-hydroxybutyrate production will be assessed using [13C4]β-hydroxybutyrate infusion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose production rate</measure>
    <time_frame>1 week</time_frame>
    <description>Change in the rate of glucose production will be assessed using [2H7]glucose infusion.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>Low Carbohydrate Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Carbohydrate Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low Carbohydrate Diet</intervention_name>
    <description>Ketogenic dietary intervention</description>
    <arm_group_label>Low Carbohydrate Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70

          -  Subjects must be able to communicate meaningfully with the investigator and must be
             legally competent to provide written informed consent

        Exclusion Criteria:

          -  chronic liver disease other than NAFLD

          -  chronic disease associated with hepatic steatosis such as diabetes mellitus

          -  use of drugs known to affect hepatic steatosis

          -  contraindications for MRI

          -  pregnancy or nursing at the time of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Panu Luukkonen, MD, PhD</last_name>
    <phone>+358094711</phone>
    <email>panu.luukkonen@helsinki.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Biomedicum 2U</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aila Karioja-Kallio</last_name>
      <phone>+358094711</phone>
      <email>ext-aila.karioja-kallio@hus.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Panu Luukkonen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

